Puma Biotechnology Inc to Discuss the Alisertib Licensing Agreement Call Transcript
Good afternoon. My name is Diego, and I will be your conference call operator today. (Operator Instructions) As a reminder, this call is being recorded. I would now like to turn the conference call over to Mariann Ohanesian, Senior Director of IR for Puma Biotechnology. You may begin your conference.
Thank you, Diego. Good afternoon, and welcome to Puma's conference call to discuss our exclusive license agreement with Takeda for the development and commercialization of alisertib, an investigational aurora kinase A inhibitor. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President and Chairman of the Board of Puma Biotechnology; and Dr. Alvin Wong, Chief Scientific Officer.
As a reminder, this call is also being webcast. The webcast will be archived on our website and available for replay for the next 90 days.
Before I turn the call over to Alan, I would like to note that during this conference call, we will make forward-looking statements within the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
